Oncotarget

Research Papers:

miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression

Peng-Fei Zhang _, Lu-Lu Sheng, Ge Wang, Mi Tian, Ling-Yin Zhu, Rui Zhang, Jing Zhang & Jin-Shui Zhu

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2016; 7:35284-35292. https://doi.org/10.18632/oncotarget.9169

Metrics: HTML 882 views  |   ?  


Abstract

Peng-Fei Zhang1,*, Lu-Lu Sheng2,*, Ge Wang1,*, Mi Tian2, Ling-Yin Zhu1, Rui Zhang1, Jing Zhang1, Jin-Shui Zhu1

1Department of Gastroenterology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, P.R. China

2Department of Emergency Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Jin-Shui Zhu, email: zhujs1803@163.com

Jing Zhang, email: jing5522724@163.com

Keywords: gastric cancer, microRNA-363, proliferation, chemo-resistance, FBW7

Received: December 17, 2015    Accepted: April 11, 2016    Published: May 4, 2016

ABSTRACT

Dysregulation of microRNA expression is involved in several pathological activities associated with gastric cancer progression and chemo-resistance. However, the role and molecular mechanisms of miR-363 in the progression and chemo-resistance of gastric cancer remain enigmatic. In this study, we validated that miR-363 expression was higher in gastric cancer tissues than in adjacent normal tissues. Multivariate analysis identifies high levels of miR-363 expression as an independent predictor for postoperative recurrence and lower overall survival. Increased miR-363 expression promotes gastric cancer cell proliferation and chemo-resistance through directly targeting the tumor suppressor F-box and WD repeat domain-containing 7 (FBW7). Clinically, our data reveal that overexpression of miR-363 correlates with the poor survival outcomes in patients with gastric cancer, and docetaxel + cisplatin + 5-FU (DCF) regimen response is impaired in patients with miR-363 overexpression. These data suggest that miR-363 may be a potential therapeutic target for gastric cancer and serve as a biomarker for predicting response to DCF regimen treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9169